Discover
NXL
Nexalin Technology, Inc.
0.38
2 x 0.27
2 x 0.46
bid
ask
+
0.05
15.15%
2 @ 04:00 PM
0.40 +0.02 (5.26%)
| Ytd | -31.90% | |
| 1y | -61.62% |
0.34
day range
0.40
0.30
52 week range
2.00
| Open | 0.36 | Prev Close | 0.33 | Low | 0.34 | High | 0.40 | Mkt Cap | 8.19M |
| Vol | 328.98K | Avg Vol | 858.66K | EPS | -0.46 | P/E | N/A | Forward P/E | -6.39 |
| Beta | 3.57 | Short Ratio | 0.56 | Inst. Own | 2.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.41 | 200-d Avg | 0.70 | 1yr Est | 3.00 |
NXL News
benzinga.com
Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Bene
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and cli
benzinga.com
Nexalin Technology Completes 8-Week Clinical Study Of Neurostimulation Protocol In Adults With Gener
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no
benzinga.com
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
Nexalin reports Brazil trial gains in anxiety, depression and sleep, plus U.S. patent protection thr
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
Nexalin Technology Announces New U.S. Patent Covering Dynamic Frequency Deep-Brain Neurostimulation
The United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: "Tr